Shots:
- The P-III (DeLLphi-304) trial evaluated Imdelltra (tarlatamab-dlle) vs SoC CT (topotecan globally excl. Japan; lurbinectedin in the US, Canada, Australia, Singapore, Korea; amrubicin in Japan) in SCLC pts (n=509) who progressed on or after 1L of Pt-based CT
- Trial met its 1EP of superior OS & 2EPs of improved PFS & PROs for dyspnea as well as cough at interim analysis, showing a 40% reduction in death risk, with mOS of 13.6 vs 8.3mos. & mPFS of 4.2 vs 3.7mos. recorded at mFU of 11.2mos. for Imdelltra & 11.7mos. for control arm; data was published in The NEJM
- Imdelltra is an immunotherapy that targets DLL3 on cancer cells & CD3 on T cells, triggering the T cells to destroy DLL3-expressing SCLC cells
Ref: Amgen| Image: Amgen | Press Release
Related News:- Amgen Reports the MHRA’s Approval of Tepezza to Treat Thyroid Eye Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
